API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Fetroja (cefiderocol) for injection is the first and only siderophore cephalosporin antibiotic. It is being evaluated for the treatment of complicated urinary tract infections & Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Lead Product(s): Cefiderocol sulfate tosylate
Therapeutic Area: Infections and Infectious Diseases Product Name: Fetroja
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
Cefiderocol Sulfate Tosylate has a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens. Fetroja achieved clinical cure in 63% of patients with Acinetobacter baumannii infections and 63% of patients with Pseudomonas aeruginosa infections.
Lead Product(s): Cefiderocol sulfate tosylate
Therapeutic Area: Infections and Infectious Diseases Product Name: Fetroja
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2022
Details:
Publication of two studies in The Lancet Infectious Diseases journal has shown the efficacy and safety of FETROJA for some of the most difficult-to-treat Gram-negative bacterial infections, including nosocomial pneumonia, bloodstream infections, sepsis, and Complicated UTIs.
Lead Product(s): Cefiderocol sulfate tosylate
Therapeutic Area: Infections and Infectious Diseases Product Name: Fetroja
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The approval was based on the nonclinical data package, including the PK/PD data package, and data from three clinical studies in complicated UTI, nosocomial pneumonia and critically ill patients with confirmed carbapenem-resistant infection.
Lead Product(s): Cefiderocol sulfate tosylate
Therapeutic Area: Infections and Infectious Diseases Product Name: Fetcroja
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020